2024-31536Notice

Considerations for Including Tissue Biopsies in Clinical Trials; Draft Guidance for Industry, Investigators, Institutions, and Institutional Review Boards; Availability

Published Date: 1/7/2025

Notice

Summary

The FDA and OHRP just dropped draft guidance to help doctors, researchers, and review boards handle tissue biopsies in clinical trials safely and smartly. This affects anyone running or reviewing trials with biopsies, including kids and adults, and aims to make these studies clearer and better. You’ve got until March 10, 2025, to send in your thoughts before the final rules roll out—so get ready to weigh in!

Analyzed Economic Effects

2 provisions identified: 1 benefits, 1 costs, 0 mixed.

Optional Biopsies for Non-Key Uses

If you take part in a clinical trial (adult or child), the draft guidance says tissue biopsies done for non-key secondary endpoints, exploratory endpoints, or unspecified future research should not be required and instead should be optional.

Biopsies Required When Medically Necessary

The draft guidance states that when biopsied tissue is the only way to get information needed to answer key trial questions—such as determining eligibility or evaluating treatment effects—those biopsies may be required for trial participation.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
1/7/2025

Department and Agencies

Department
Independent Agency
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register